Nanocarrier vaccines for SARS-CoV-2

Jatin Machhi; Farah Shahjin; Srijanee Das; Milankumar Patel; Mai Mohamed Abdelmoaty; Jacob D. Cohen; Preet Amol Singh; Ashish Baldi; Neha Bajwa; Raj Kumar; Lalit K. Vora; Tapan A. Patel; Maxim D. Oleynikov; Dhruvkumar Soni; Pravin Yeapuri; Insiya Mukadam; Rajashree Chakraborty; Caroline G. Saksena; Jonathan Herskovitz; Mahmudul Hasan; David Oupicky; Suvarthi Das; Ryan F. Donnelly; Kenneth S. Hettie; Linda Chang; Howard E. Gendelman; Bhavesh D. Kevadiya

doi:10.1016/j.addr.2021.01.002

Nanocarrier vaccines for SARS-CoV-2

Jatin Machhi
, Farah Shahjin
, Srijanee Das
, Milankumar Patel
, Mai Mohamed Abdelmoaty
, Jacob D. Cohen
, Preet Amol Singh
, Ashish Baldi
, Neha Bajwa
, Raj Kumar
, Lalit K. Vora
, Tapan A. Patel
, Maxim D. Oleynikov
, Dhruvkumar Soni
, Pravin Yeapuri
, Insiya Mukadam
, Rajashree Chakraborty
, Caroline G. Saksena
, Jonathan Herskovitz
, Mahmudul Hasan

David Oupicky, Suvarthi Das, Ryan F. Donnelly, Kenneth S. Hettie, Linda Chang, Howard E. Gendelman, Bhavesh D. Kevadiya

Research output: Contribution to journal › Review article › peer-review

91 Scopus citations

Abstract

The SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death associated with substantive social, economic and societal impacts. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and the principal global effort to end the pandemic. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery.

Original language	English
Pages (from-to)	215-239
Number of pages	25
Journal	Advanced Drug Delivery Reviews
Volume	171
DOIs	https://doi.org/10.1016/j.addr.2021.01.002
State	Published - Apr 2021
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2021

Funding

Funders	Funder number
National Institute on Aging	R01AG043540

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19 vaccine
Nanovaccine
SARS-CoV-2
mRNA vaccine

Access to Document

10.1016/j.addr.2021.01.002

Cite this

Machhi, J., Shahjin, F., Das, S., Patel, M., Abdelmoaty, M. M., Cohen, J. D., Singh, P. A., Baldi, A., Bajwa, N., Kumar, R., Vora, L. K., Patel, T. A., Oleynikov, M. D., Soni, D., Yeapuri, P., Mukadam, I., Chakraborty, R., Saksena, C. G., Herskovitz, J., ... Kevadiya, B. D. (2021). Nanocarrier vaccines for SARS-CoV-2. Advanced Drug Delivery Reviews, 171, 215-239. https://doi.org/10.1016/j.addr.2021.01.002

@article{6e917b857f2544babf459252894bec31,

title = "Nanocarrier vaccines for SARS-CoV-2",

abstract = "The SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death associated with substantive social, economic and societal impacts. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and the principal global effort to end the pandemic. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery.",

keywords = "COVID-19 vaccine, Nanovaccine, SARS-CoV-2, mRNA vaccine",

author = "Jatin Machhi and Farah Shahjin and Srijanee Das and Milankumar Patel and Abdelmoaty, \{Mai Mohamed\} and Cohen, \{Jacob D.\} and Singh, \{Preet Amol\} and Ashish Baldi and Neha Bajwa and Raj Kumar and Vora, \{Lalit K.\} and Patel, \{Tapan A.\} and Oleynikov, \{Maxim D.\} and Dhruvkumar Soni and Pravin Yeapuri and Insiya Mukadam and Rajashree Chakraborty and Saksena, \{Caroline G.\} and Jonathan Herskovitz and Mahmudul Hasan and David Oupicky and Suvarthi Das and Donnelly, \{Ryan F.\} and Hettie, \{Kenneth S.\} and Linda Chang and Gendelman, \{Howard E.\} and Kevadiya, \{Bhavesh D.\}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = apr,

doi = "10.1016/j.addr.2021.01.002",

language = "אנגלית",

volume = "171",

pages = "215--239",

journal = "Advanced Drug Delivery Reviews",

issn = "0169-409X",

publisher = "Elsevier B.V.",

}

Machhi, J, Shahjin, F, Das, S, Patel, M, Abdelmoaty, MM, Cohen, JD, Singh, PA, Baldi, A, Bajwa, N, Kumar, R, Vora, LK, Patel, TA, Oleynikov, MD, Soni, D, Yeapuri, P, Mukadam, I, Chakraborty, R, Saksena, CG, Herskovitz, J, Hasan, M, Oupicky, D, Das, S, Donnelly, RF, Hettie, KS, Chang, L, Gendelman, HE & Kevadiya, BD 2021, 'Nanocarrier vaccines for SARS-CoV-2', Advanced Drug Delivery Reviews, vol. 171, pp. 215-239. https://doi.org/10.1016/j.addr.2021.01.002

TY - JOUR

T1 - Nanocarrier vaccines for SARS-CoV-2

AU - Machhi, Jatin

AU - Shahjin, Farah

AU - Das, Srijanee

AU - Patel, Milankumar

AU - Abdelmoaty, Mai Mohamed

AU - Cohen, Jacob D.

AU - Singh, Preet Amol

AU - Baldi, Ashish

AU - Bajwa, Neha

AU - Kumar, Raj

AU - Vora, Lalit K.

AU - Patel, Tapan A.

AU - Oleynikov, Maxim D.

AU - Soni, Dhruvkumar

AU - Yeapuri, Pravin

AU - Mukadam, Insiya

AU - Chakraborty, Rajashree

AU - Saksena, Caroline G.

AU - Herskovitz, Jonathan

AU - Hasan, Mahmudul

AU - Oupicky, David

AU - Das, Suvarthi

AU - Donnelly, Ryan F.

AU - Hettie, Kenneth S.

AU - Chang, Linda

AU - Gendelman, Howard E.

AU - Kevadiya, Bhavesh D.

PY - 2021/4

Y1 - 2021/4

N2 - The SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death associated with substantive social, economic and societal impacts. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and the principal global effort to end the pandemic. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery.

AB - The SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death associated with substantive social, economic and societal impacts. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and the principal global effort to end the pandemic. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery.

KW - COVID-19 vaccine

KW - Nanovaccine

KW - SARS-CoV-2

KW - mRNA vaccine

UR - https://www.scopus.com/pages/publications/85102116534

U2 - 10.1016/j.addr.2021.01.002

DO - 10.1016/j.addr.2021.01.002

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 33428995

AN - SCOPUS:85102116534

SN - 0169-409X

VL - 171

SP - 215

EP - 239

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

ER -

Nanocarrier vaccines for SARS-CoV-2

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this